FGF19 and diabetes mellitus: LCA is an agonist of farnesoid X receptor (FXR), activation of which reduces BA synthesis in the liver via fibroblast growth factor-19 signaling (50, 51), whereas GUDCA is an antagonist for FXR, recently shown to improve metabolic endpoints in humans related to diabetes (52).